Italygeneva

MILAN, Italy and GENEVA, Switzerland - The Effect of Short-course Oral Treatment With Cladribine Tablets on Annualized Relapse Rate was Significant as Early as 12 Weeks After Initiation of Treatment and Sustained Through to the 96 Weeks of the Study Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today new data from post-hoc analyses of the 2-year (96-week) placebo-controlled CLARITYa Phase III trial using Cladribine Tablets (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis.